Spirea
Elevating the Therapeutic Potential of ADCs in Cancer and Beyond with Our Unique Multivalent ELIVATE Linker Technology
Elevating the Therapeutic Potential of ADCs in Cancer and Beyond with Our Unique Multivalent ELIVATE Linker Technology
Spirea Limited, founded in 2017 and headquartered in the United Kingdom, is focused on unlocking the next generation of antibody drug conjugates for targeted cancer treatments. Their slogan, "Unlocking the next generation of antibody drug conjugates," encapsulates their mission to develop more effective and safer therapies. The company's innovative technology is poised to revolutionize the treatment of solid tumors with a pipeline of superior and differentiated antibody drug conjugates. In a recent milestone, Spirea secured a significant £2.40M in a Venture Round investment on 14 June 2022. Notable investors include Angel CoFund, Cambridge Angels, R42, o2h Ventures, SyndicateRoom, Jonathan Milner, and University of Cambridge Enterprise. With this latest investment, Spirea is poised to advance its cutting-edge biotechnology within the Biotechnology, Health Care, and Pharmaceutical industries, marking an exciting development within the startup landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £2.40M | 7 |
|
14 Jun 2022 |
| Seed Round | Unknown | 2 |
|
22 Jan 2021 |
| Seed Round | Unknown | 2 | Start Codon, Meltwind Advisory | 13 Jul 2020 |
| Pre Seed Round | Unknown | 1 | University of Cambridge Enterprise | 04 Dec 2019 |
| Pre Seed Round | Unknown | 1 |
|
26 Jul 2018 |
No recent news or press coverage available for Spirea.
We care about your data, and we'd love to use cookies make your experience better.